title: Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease.
abstract: OBJECTIVE
  There has been significant controversy over the relationship between Helicobacter pylori infection and reflux esophagitis. We investigated the effects of eradicating H. pylori on the reflux esophagitis found in patients with peptic ulcers.
  
  
  METHODS
  Prospective posteradication evaluations were conducted yearly in 162 H. pylori-positive patients who had reflux esophagitis together with peptic ulcer disease (4 women and 158 men, mean age = 49.1 yr). The Los Angeles classification of the patients' esophagitis was: grade A, 90; grade B, 63; and grade C, 9. The follow-up evaluations began 1 to 2 months after completion of the eradication treatment (mean time of follow-up = 22 mo), and consisted of endoscopy and an interview focusing on heartburn.
  
  
  RESULTS
  Six patients were withdrawn from the study because of adverse drug reactions or a failure to regularly keep their appointments. After eradication therapy, we observed endoscopically that reflux esophagitis had improved in 87 (55.8%) of the 156 patients. The improvement rate was significantly higher in patients cured of infection (60.8%) than in those with persistent H. pylori infection (38.9%) (P = 0.04). Body mass index (odds ratio = 0.86, 95% confidence interval [CI] = 0.76-0.97), cure of infection (3.68, 95% CI = 1.56-8.69), the absence of a hiatal hernia (3.90, 95% CI = 1.83-8.28), and an ulcer located in the duodenum (2.75, 95% CI = 1.33-5.70) were identified as significant independent factors for the improvement of reflux esophagitis.
  
  
  CONCLUSIONS
  In patients with reflux esophagitis associated with duodenal ulcer, a significant improvement in pre-existing reflux esophagitis was noted after H. pylori eradication.
authors.affiliation: Department of Internal Medicine, Nippon Kokan Fukuyama Hospital, Japan.
authors.forename: Kuniharu
authors.initials: K
authors.lastname: Ishiki
authors.forename: Motowo
authors.initials: M
authors.lastname: Mizuno
authors.forename: Susumu
authors.initials: S
authors.lastname: Take
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nagahara
authors.forename: Tomowo
authors.initials: T
authors.lastname: Yoshida
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okada
authors.forename: Kenji
authors.initials: K
authors.lastname: Yokota
authors.forename: Keiji
authors.initials: K
authors.lastname: Oguma
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Shiratori
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000150:complications* / Q000188:drug therapy; D004942:Esophagitis, Peptic / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D017291:Clarithromycin